1-methoxy-4-(4-methylpent-1-yn-1-yl)benzene | 1379664-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-methoxy-4-(4-methylpent-1-yn-1-yl)benzene
• 英文别名: 1-Methoxy-4-(4-methyl-pent-1-ynyl)-benzene；1-methoxy-4-(4-methylpent-1-ynyl)benzene
• CAS: 1379664-14-8
• 化学式: C₁₃H₁₆O
• 分子量: 188.269
• InChiKey: KNTPYXDXAQYCQK-UHFFFAOYSA-N

物化性质

• 沸点：
  277.2±23.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-methoxy-4-(4-methylpent-1-yn-1-yl)benzene 、 2,4-二氯苯甲醛 在 三氟化硼乙醚 作用下， 以 二氯甲烷 为溶剂， 以70%的产率得到(E)-2-(2,4-dichlorobenzylidene)-1-(4-methoxyphenyl)-4-methylpentan-1-one
  参考文献：
  名称：

  Synthesis and antiproliferative activity of α-branched α,β-unsaturated ketones in human hematological and solid cancer cell lines

  摘要：

  A series of alpha-branched alpha,beta-unsaturated ketones were prepared via boron trifluoride etherate mediated reaction between arylalkynes and carboxaldehydes. The evaluation of the antiproliferative activity over hematological (NB4) and solid cancer (A549, MCF-7) cell lines provided a structure-activity relationship. 5-Parameter QSAR equations were built which were able to explain 80%-92% of the variance in activity. The resulting selective lead compound showed IC50 value 0.6 mu M against the hematological cell line and did not cause apoptosis, but blocked cell cycle in G0/G1. Moreover, it was demonstrated that this compound enhances and accelerates retinoic acid induced granulocytic differentiation. (C) 2015 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2015.05.012
• 作为产物：
  描述：

  4-乙炔基苯甲醚 在 N-溴代丁二酰亚胺(NBS) 、 三正丁胺 、 2,4,5,6-四(9H-咔唑-9-基)异酞腈 、 silver nitrate 作用下， 以 乙酸乙酯 、 丙酮 为溶剂， 反应 27.0h， 生成 1-methoxy-4-(4-methylpent-1-yn-1-yl)benzene
  参考文献：
  名称：

  Visible-Light-Driven α-Aminoalkyl Radical-Mediated C(sp³)–C(sp) Cross-Coupling of Iodoalkanes and Alkynyl Bromides

  摘要：

  DOI：

  10.1021/acs.orglett.2c02018

文献信息

• Regioselective Cycloaddition of 3-Azetidinones and 3-Oxetanones with Alkynes through Nickel-Catalysed Carbon-Carbon Bond Activation
  作者：Kelvin Y. T. Ho、Christophe Aïssa

  DOI：10.1002/chem.201200167

  日期：2012.3.19

  Get in the ring! The first examples of transition‐metal‐catalysed CC bond activation of 3‐azetidinones and 3‐oxetanones are reported. In the presence of a nickel catalyst and alkynes, a regioselective and high‐yielding [4+2] cycloaddition occurs, leading to the formation of pyridinones, pyranones and eventually 4,5‐disubstituted 3‐hydroxypyridines (see scheme).

  加油！过渡金属催化的C的第一实施例报道C键活化的3-氮杂环丁酮和3-氧杂环丁烷酮。在镍催化剂和炔烃的存在下，会发生区域选择性和高产率的[4 + 2]环加成反应，导致形成吡啶酮，吡喃酮，并最终形成4,5-二取代的3-羟基吡啶（参见方案）。
• On the Regioselectivity of the Nickel-Catalyzed Insertion of Alkynes into the Carbon–Carbon Bond of Oxetan-3-one
  作者：Christophe Aïssa、Manuel Barday、Christopher Janot、Daniel Clare、Caitlin Carr-Knox、Bradley Higginson、Kelvin Ho

  DOI：10.1055/s-0036-1589052

  日期：2017.8

  of unsymmetrical alkynes into the carbon–carbon bond of oxetan-3-one in the presence of a nickel catalyst has revealed a strong directing effect of a 2-thienyl substituent. This effect is larger than those of 2-vinylbenzene, trimethylsilyl, aryl, or 3-thienyl groups. The study of the regioselectivity of insertion of unsymmetrical alkynes into the carbon–carbon bond of oxetan-3-one in the presence of

  作为镍合成高级特别策略的一部分发布 抽象的 在镍催化剂存在下，将不对称炔烃插入oxetan-3-one的碳-碳键中的区域选择性研究表明，2-噻吩基取代基具有很强的导向作用。该作用大于2-乙烯基苯，三甲基甲硅烷基，芳基或3-噻吩基的作用。 在镍催化剂存在下，将不对称炔烃插入oxetan-3-one的碳-碳键中的区域选择性研究表明，2-噻吩基取代基具有很强的导向作用。该作用大于2-乙烯基苯，三甲基甲硅烷基，芳基或3-噻吩基的作用。
• PYRIDO[3,4-B]INDOLES AND METHODS OF USE
  申请人：HUNG David T.

  公开号：US20090270412A1

  公开（公告）日：2009-10-29

  This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的杂环化合物，可用于调节个体中的组胺受体。描述了吡啶并[3,4-b]吲哚类化合物，以及包含该化合物的药物组合物和使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20130190303A1

  公开（公告）日：2013-07-25

  This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及可用于调节组织胺受体的新化合物。其中描述了新的桥接杂环[4,3-b]吲哚化合物。还提供了制药组合物，包括含有该化合物的制药组合物。还提供了使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• US8338447B2
  申请人：——

  公开号：US8338447B2

  公开（公告）日：2012-12-25